Clinic
J.P. Wornock M.D. P.A.
J.P. Wornock M.D. P.A. was paid $7.79M by Medicaid between Jan 2018 and Dec 2024, across 69 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 34% of everything it billed.
33Billing provider infoJ.P. WORNOCK M.D. P.A.
SEARCY, AR 72143
SEARCY, AR 72143
33aNPI1316918576assigned 01/27/2006
33bProvider typePrimary Care Clinic/Center
28Total paid$7.79M
24GClaims211,139
24DCodes billed69
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Primary Care Clinic/Center providers in Arkansas
Rank by total paid#3 of 64
Median peer was paid$92K
This provider vs. median85×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,277 | $745K | |
| 2019 | 24,925 | $910K | |
| 2020 | 25,271 | $889K | |
| 2021 | 37,518 | $1.34M | |
| 2022 | 38,702 | $1.42M | |
| 2023 | 32,086 | $1.27M | |
| 2024incomplete | 31,360 | $1.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 34% | 40,739 | 36,431 | $2.66M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 26% | 59,658 | 52,734 | $2.03M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 8.4% | 14,227 | 13,099 | $653K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 5.8% | 13,271 | 11,260 | $454K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.1% | 6,283 | 5,712 | $321K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.6% | 5,354 | 4,828 | $279K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.3% | 4,873 | 4,496 | $260K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.6% | 17,801 | 8,248 | $202K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.4% | 4,256 | 3,709 | $183K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.1% | 2,995 | 2,775 | $164K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.0% | 2,085 | 1,878 | $81K |
| 90686 | <1% | 5,952 | 5,631 | $77K |
57 more codes
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,154 | $66K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 512 | $58K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,521 | $29K |
| 87807 | <1% | 2,170 | $26K | |
| 90698 | <1% | 1,947 | $25K | |
| 90670 | <1% | 2,005 | $22K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,044 | $21K |
| 81002 | <1% | 6,983 | $20K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 903 | $17K |
| 90633 | <1% | 1,558 | $17K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,005 | $13K |
| 90681 | <1% | 1,032 | $12K | |
| 90651 | <1% | 752 | $9K | |
| 90734 | <1% | 771 | $8K | |
| 90697 | <1% | 482 | $7K | |
| 90744 | <1% | 644 | $7K | |
| 90649 | <1% | 776 | $7K | |
| 90656 | <1% | 441 | $6K | |
| 90677 | <1% | 470 | $6K | |
| 87428 | <1% | 85 | $5K | |
| 99381 | <1% | 108 | $5K | |
| 90671 | <1% | 405 | $5K | |
| 90688 | <1% | 463 | $4K | |
| 90619 | <1% | 309 | $4K | |
| 90715 | <1% | 262 | $3K | |
| 81025 | <1% | 358 | $3K | |
| 91321 | <1% | 138 | $3K | |
| 90710 | <1% | 185 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 156 | $2K |
| 90620 | <1% | 188 | $2K | |
| 90657 | <1% | 223 | $2K | |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | <1% | 1,019 | $2K |
| 95115 | <1% | 140 | $1K | |
| 90696 | <1% | 131 | $1K | |
| 99383 | <1% | 38 | $1K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 166 | $1K |
| 90707 | <1% | 71 | $803.98 | |
| 90716 | <1% | 71 | $794.42 | |
| 99382 | <1% | 14 | $732.12 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 15 | $672.94 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 13 | $669.20 |
| 69209 | <1% | 58 | $628.71 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 313 | $579.18 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15 | $491.82 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 72 | $481.16 |
| 90621 | <1% | 38 | $449.28 | |
| 91322 | <1% | 26 | $373.50 | |
| 90648 | <1% | 36 | $355.45 | |
| 99173 | <1% | 13 | $265.20 | |
| 90655 | <1% | 26 | $248.56 | |
| 90723 | <1% | 16 | $197.10 | |
| 90685 | <1% | 17 | $152.96 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 746 | $85.40 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 258 | $2.50 |
| 3078F | 0% | 116 | $0.00 | |
| 3079F | 0% | 30 | $0.00 | |
| 3074F | 0% | 137 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWORNOCK, JOHN (OWNER)